Martin Dreyling
马丁·德雷林
MD, PhD
Professor of Medicine; Head, Lymphoma Section医学教授；淋巴瘤科主任
👥Biography 个人简介
Prof. Martin Dreyling is one of Europe's foremost authorities on mantle cell lymphoma (MCL). He led the landmark TRIANGLE trial, which redefined frontline MCL treatment by incorporating ibrutinib into induction and maintenance, challenging the established role of autologous stem cell transplantation.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
TRIANGLE Trial — Redefining MCL Frontline Therapy
Led the TRIANGLE trial demonstrating that ibrutinib added to frontline R-CHOP/R-DHAP and maintenance significantly improved outcomes in MCL, questioning the necessity of autologous SCT in the BTK inhibitor era.
Representative Works 代表性著作
Ibrutinib Combined with Immunochemotherapy with or without Autologous Stem-Cell Transplantation in Previously Untreated Patients with Mantle Cell Lymphoma (TRIANGLE)
The Lancet (2024)
Randomized trial showing ibrutinib-containing regimens superior to standard immunochemotherapy+ASCT in frontline MCL, reshaping treatment guidelines.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Sebastian Bauer
University Hospital Essen (Universitätsklinikum Essen)
Suzanne George
Dana-Farber Cancer Institute / Harvard Medical School
Marcia S. Brose
Sidney Kimmel Cancer Center, Thomas Jefferson University
Lori J. Wirth
Massachusetts General Hospital, Harvard Medical School
关注 马丁·德雷林 的研究动态
Follow Martin Dreyling's research updates
留下邮箱，当我们发布与 Martin Dreyling（LMU University Hospital Munich）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment